Company Overview#
MEDIIMG is a medical imaging AI company specializing in cerebrovascular disease diagnostics. The company develops solutions that convert conventional 2D black-and-white TOF-MRA images into 3D color visualizations and quantitative hemodynamic data. By providing clear cerebrovascular biomarkers, MEDIIMG assists clinicians in assessing blood vessel health and analyzing risk factors.
Technology & Product#
The core product is NeuFlow, an FDA-approved 3D Color MRA software and the first MRA-based software to analyze cerebrovascular wall shear stress. NeuFlow processes standard TOF-MRA scans to extract 3D color images and quantitative wall shear stress data, expressed as a Shear-induced Gray (SIG) biomarker, without requiring complex clinical setups or advanced imaging hardware. It generates comprehensive AI Health Reports that offer precise vessel-specific measurements, aiding in clinical decision-making for cerebrovascular conditions.
Market & Use Cases#
NeuFlow targets hospitals and diagnostic imaging centers dealing with neurological and cerebrovascular health. It is used by radiologists and neurologists to predict and monitor the risk of conditions such as cerebral aneurysms. The software integrates seamlessly into existing workflows, allowing rapid measurements and quantitative data extraction from standard MRA scans.
Traction & References#
NeuFlow received FDA 510(k) clearance in October 2024 and is also approved by the MFDS in Korea. MEDIIMG has established a robust clinical research network, collaborating with major institutions including Seoul National University Hospital, Samsung Medical Center, Ajou University Hospital, and Jeonbuk National University Hospital. The company was selected for the TIPS program in 2024.
Collaboration Relevance#
MEDIIMG is highly relevant for medical imaging platforms and PACS providers looking to integrate advanced neurovascular AI capabilities. It also presents a strong partnership opportunity for global healthcare equipment manufacturers and neurology-focused clinical research institutions seeking validated cerebrovascular biomarkers.